Inimmune CSO Jay Evans to present an update on clinical stage programs at the International Precision Vaccine Conference in Rome, Italy on October 5-6
2023-09-28
疫苗免疫疗法临床1期
MISSOULA, Mont., Sept. 28, 2023 /PRNewswire/ -- Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will be a speaker at the International Precision Vaccines Conference (https://precisionvaccines2023.com/) in Rome, Italy on October 5-6.
The International Precision Vaccine Conference (IPVC) will bring together experts in vaccinology and immunology from academia, government, and industry to provide updates on Precision Vaccines: Biomarkers of Vaccine Safety and Efficacy in Vulnerable Populations. "Inimmune is looking forward to participating in the IPVC and contributing to discussions on the advancement of innovative new vaccines and immunotherapeutics", said Dr. Evans.
Inimmune transitioned from a pre-clinical to clinical stage company in 2023 with the initiation of a Phase I clinical trial with a new disease modifying treatment for seasonal allergic rhinitis. Additional immuno-oncology and vaccine Phase I clinical trials are expected in early 2024. Dr. Evans will provide an update on Inimmune's progress in advancing new vaccine adjuvants and immunotherapy solutions, including a project in collaboration with Boston Children's Hospital's Precision Vaccines Program in developing PVP-037 a small molecule TLR7 agonistTLR7 agonist.
Vaccine adjuvants, like those being developed at Inimmune, are used to enhance the immune response to vaccines. Adjuvants are also important in other areas of medicine, such as immuno-oncology, allergy, and autoimmunity. Inimmune is focused on developing innovative vaccine adjuvants and delivery systems to enhance global health with a rapidly growing pipeline of innovative immunotherapeutics.
"We are honored to host Dr. Evans and are grateful for Inimmune's support in co-sponsoring the IPVC conference. Application of precision adjuvants holds great promise across a range of indications to prevent and treat disease in vulnerable populations", said Ofer Levy, M.D., Ph.D., Director, Precision Vaccines Program at Boston Children's Hospital and Co-Organizer of IPVC.
The conference includes two full days of seminars, poster sessions, and interactive forums to discuss and reflect on recent studies of vaccine safety and immunogenicity relevant to vulnerable populations. This year's event will be held on October 5-6 at the Parco dei Principi Grand Hotel & Spa in Rome, Italy.
About Inimmune:
Inimmune Corp. (Missoula, MT) is a privately held biotechnology company focused on the discovery and development of innovative immunotherapeutics, adjuvants and vaccines. Inimmune is harnessing the human immune system to create safe and effective treatments for allergy, infectious disease, autoimmunity and cancer. Their laboratories and offices are housed in the Montana Technology Enterprise Center (MonTEC) in Missoula, MT (USA).
For more information on Inimmune's research and development of novel vaccine adjuvants and delivery systems, please visit www.inimmune.com.
Contact:
Media Relations
Phone: (406)-541-5913
Email: [email protected]
SOURCE Inimmune
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。